These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 10368520

  • 1. Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke.
    Castelli WP.
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S349-56. PubMed ID: 10368520
    [Abstract] [Full Text] [Related]

  • 2. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 3. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [Abstract] [Full Text] [Related]

  • 4. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O.
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [Abstract] [Full Text] [Related]

  • 5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 6. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States.
    Schwingl PJ, Ory HW, Visness CM.
    Am J Obstet Gynecol; 1999 Jan 11; 180(1 Pt 1):241-9. PubMed ID: 9914611
    [Abstract] [Full Text] [Related]

  • 7. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

  • 8. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.
    Lancet; 1995 Dec 16; 346(8990):1589-93. PubMed ID: 7500750
    [Abstract] [Full Text] [Related]

  • 9. Benefits and risks of oral contraceptives.
    Sherif K.
    Am J Obstet Gynecol; 1999 Jun 16; 180(6 Pt 2):S343-8. PubMed ID: 10368519
    [Abstract] [Full Text] [Related]

  • 10. Epidemiology of oral contraceptives and cardiovascular disease.
    Chasan-Taber L, Stampfer MJ.
    Ann Intern Med; 1998 Mar 15; 128(6):467-77. PubMed ID: 9499331
    [Abstract] [Full Text] [Related]

  • 11. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G, Kohlmeier L, Brenner H.
    Eur J Clin Nutr; 1998 Oct 15; 52(10):711-5. PubMed ID: 9805216
    [Abstract] [Full Text] [Related]

  • 12. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R.
    Contraception; 1997 Sep 15; 56(3):129-40. PubMed ID: 9347202
    [Abstract] [Full Text] [Related]

  • 13. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr 15; 7(1):3-6. PubMed ID: 12320047
    [Abstract] [Full Text] [Related]

  • 14. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives.
    Roy S.
    Am J Obstet Gynecol; 1999 Jun 15; 180(6 Pt 2):S364-8. PubMed ID: 10368522
    [Abstract] [Full Text] [Related]

  • 15. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D, Wildemeersch D, Verougstraete A, Creatsas G.
    Int J Fertil Menopausal Stud; 1995 Jun 15; 40 Suppl 2():73-9. PubMed ID: 8574253
    [Abstract] [Full Text] [Related]

  • 16. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa Heart Study.
    Greenlund KJ, Webber LS, Srinivasan S, Wattigney W, Johnson C, Berenson GS.
    Ann Epidemiol; 1997 Nov 15; 7(8):561-7. PubMed ID: 9408552
    [Abstract] [Full Text] [Related]

  • 17. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC.
    Contracept Fertil Sex (Paris); 1991 Apr 15; 19(4):285-8. PubMed ID: 12343220
    [Abstract] [Full Text] [Related]

  • 18. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism.
    Walsh BW, Sacks FM.
    J Clin Invest; 1993 May 15; 91(5):2126-32. PubMed ID: 8486779
    [Abstract] [Full Text] [Related]

  • 19. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD, Lawrenson RA.
    Am J Obstet Gynecol; 1998 Sep 15; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [Abstract] [Full Text] [Related]

  • 20. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G.
    Int J Fertil Menopausal Stud; 1994 Sep 15; 39(5):283-91. PubMed ID: 7820162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.